Burjeel Holdings Plc · ADX:BURJEEL
Burjeel — Investor Presentation (March 2025)
52 slides from Burjeel's investor presentation, March 2025
Slide 1: Burjeel Holdings: Leading Super-Specialty Healthcare Provider in MENA
March 2025 Burjeel Holdings Leading Super-Specialty Healthcare Provider in MENA
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Burjeel Holdings PLC None of the Company or its subsidiaries or any of their affiliates or based on publicly available information and non-public advisors make any representation or warranty as to the fairness, information to assist you in making a p
Slide 3: Contents
Contents 02 03 Investment Strategic Case Priorities 01 Burjeel Holdings at a Glance 04 Performance Update 06 05 Appendix Guidance
Slide 4: Burjeel Holdings at a Glance
01 Burjeel Holdings at a Glance Leading Super-Specialty Healthcare Provider in MENA
Slide 5: Leading Integrated Healthcare Network in the MENA
Leading Integrated Healthcare Network in the MENA Expanding market presence UAE, Oman & KSA 100 19% Geographical Medical assets Inpatient market presence incl. 19 hospitals1 share in the UAE2 1,730 6.5 million 1,744 Bed capacity3 Total patients4 Doctors3 Diversified portfolio of brands AAA ESG MSCI
Slide 6: High Quality, Large-scale Portfolio of Assets Across Geographies
High Quality, Large-scale Portfolio of Assets Across Geographies Segmental revenue contribution Geographic revenue contribution Hospital Medical Centers 1% Pharmacies 87% Physiotherapy 88% Dubai & centers 1% Other 9% Northern Emirates Abu Dhabi, Hospitals Al Dhafra & Al Ain 10% Medical Centers 4% Om
Slide 7: Business model
1 2 Business 1 Differentiating capabilities model • Level I & II Trauma Center • Centralised Lab Serving all • Level III Tertiary NICU • Nuclear Medicine socio-economic • Physio & Rehab Care • Department of Thalassemia groups • Intraoperative MRI • Advanced Center for Research • Da Vinci Xi robotic
Slide 8: Transforming Cancer Care: The UAE's Leading National Network
5 Expanding geographically Transforming Cancer Care: The UAE’s Leading National Network Burjeel Cancer Institute Diversified Referral Pathways Clinical Governance (Burjeel Medical City) Strengthening Oncology Access & Research Hub for high-end specialized oncology treatments Pathology, AI & Molecula
Slide 9: Advancing Women & Children's Healthcare Offering
Advancing Women & Children’s Healthcare Offering Partnered with the "Father of Fetal The UAE’s largest fertility center, Medicine," to provide fetal care for high- which commenced operations in risk pregnancies. First in MENA to September 2024 and became fully perform in-utero spina bifida repair. o
Slide 10: Strategic Priorities
02 Strategic Priorities Leading Super-Specialty Healthcare Provider in MENA
Slide 11: Strategic Priorities: Growth Assets, Operational Excellence, Leadership
5 Expanding geographically Ramp-up of Growth Assets Operational Excellence • Use young asset fleet to drive • Invest in clinical and nursing volume through enhanced utilization teams to enhance patient care • Position Burjeel Medical City • Lead in medical education as a primary growth driver and gl
Slide 12: Strategic Growth Pillars
5 Expanding geographically Strategic Growth Pillars Ramp-up of Growth Assets Increasing Patient Yield Operational Excellence Geographic Expansion Group Revenue Patient Yield Group EBITDA Margin Revenue from UAE Expansion Single 5,010 12%-14% Mid-Term Mid-Term Mid-Term ‘24 ‘24 754 Digit ‘24 19% 25%-2
Slide 13: Investment Case
03 Investment Case Leading Super-Specialty Healthcare Provider in MENA
Slide 14: Investment Case Highlights
World-class super- Expanding geographically specialty care through high-return and offering driving patient low-CAPEX opportunities yield growth Accelerating Leading position in large, growing & digitization resilient market to drive operational and medical excellence Well-invested multi- Cash-gener
Slide 15: Super-Specialty Care Offering Driving Patient Yields
51 World-classgeographically Expanding super-specialty care Super-Specialty Care Offering Driving Patient Yields Unmatched Momentum in Scaling Maximizing Patient Growth & Yield Da Vinci Xi system Innovation & Expertise Multi-Organ & Bone Marrow Transplants Liver & Kidney Transplants 32 (100% success
Slide 16: 2024: A Landmark Year for Multi-Organ Transplants
51 World-classgeographically Expanding super-specialty care 2024: A Landmark Year for Multi-Organ Transplants The UAE’s first ABO The UAE’s first pediatric incompatible transplant liver transplant ZERO 16 7 Living Donor Kidney Transplants 16 1 Living Donor Liver Transplants Mortalities and Rejection
Slide 17: Robust Talent Investments Powering Innovation & Research Capabilities
1 World-class super-specialty care Robust Talent Investments Powering Innovation & Research Capabilities Highly skilled and growing talent pool UAE’s Premier Research Hub: Advancing Science & Innovation +798 Doctors Axiom Space Partnership: Exploring microgravity’s role in disease understanding, dru
Slide 18: UAE Market Leader with a Prominent Position Across Segments
2 Leading position UAE Market Leader with a Prominent Position Across Segments Number of beds by key players1, as of December 2022 #1 inpatient platform in the UAE by private market volumes Beds excl. LTC in UAE 1,660 3 135 1,361 Beds in Oman 1,161 1,077 1,071 300 Focus on specialised and complex LT
Slide 19: Large, Growing and Resilient Addressable Market
2 Leading position Large, Growing and Resilient Addressable Market FY 2022 UAE & Oman & KSA market size1 $104bn Total healthcare expenditure (USD bn) 132 GCC market size2 112 $85bn UAE & Oman & KSA market size1 85 93 1.9x $27bn 69 UAE & Oman market size1 $1.4bn Burjeel Holdings revenue (FY 2024) 202
Slide 20: Unique Business Model Leveraging Multiple Touchpoints
3 Well-invested multi-brand network Unique Business Model Leveraging Multiple Touchpoints CAPEX spent from inception to FY'24 AED 4.7bn Well-invested and a full-scale hub-and-spoke model enables the Group to capture value across the entire patient pathway through multiple touchpoints – driving reven
Slide 21: Leading Brand Portfolio Serving Entire Socioeconomic Spectrum
3 Well-invested multi-brand network Leading Brand Portfolio Serving Entire Socioeconomic Spectrum Diverse brand portfolio and network Brands creates favourable negotiating position with insurance payers 11 Hospitals2 Insurance payers are the largest revenue 4 Hospitals 2 Hospitals Assets1 9 Medical
Slide 22: High-Growth Asset Mix with Significant Utilization Runway
4 High-growth asset mix High-Growth Asset Mix with Significant Utilization Runway Asset maturity split for hospitals1 Burjeel Medical City – significant opportunity to ramp up utilization with superior patient yields 37% Growth – high FY 2024 Mature Burjeel Hospital, Abu Dhabi High-Growth Burjeel Me
Slide 23: Multi-Pronged Expansion Strategy: Unlock Solid Growth Potential
5 Expanding geographically Multi-Pronged Expansion Strategy: Unlock Solid Growth Potential Key region of focus – UAE & KSA Expansion strategy pillars Expanding World-Class Healthcare Network KSA to drive our geographic expansion 1 Across Emerging UAE Communities Zero-capex expansion into Africa, thr
Slide 24: Expanding Reach, Enhancing Care: Burjeel's Growth Plan across the UAE
5 Expanding geographically Expanding Reach, Enhancing Care: Burjeel’s Growth Plan across the UAE Launch of 1 hospital, The Group will expand its Burjeel-branded network with a hospital, a day surgery center in 1 day surgery center, 11 specialized Dubai and the Northern Emirates, and 11 specialized m
Slide 25: PhysioTherabia – Entering High Potential KSA Market
5 Expanding geographically PhysioTherabia – Entering High Potential KSA Market Highly attractive entry proposition Launched first premier physiotherapy centers 60 + Physical therapy, rehabilitation and wellness centers in 12 KSA cities in a joint venture (50:50) with Leejam Company 29 centers Physio
Slide 26: Specialized Day Surgery Centers – Disruptive Innovation in Saudi Healthcare Market
5 Expanding geographically Specialized Day Surgery Centers – Disruptive Innovation in Saudi Healthcare Market Strong rationale for expansion in KSA Burjeel One – First Day Surgery Center in Riyadh • Promising macro and demographic trends o GDP growth of c.5.5% p.a. • Located in Irqah, Northwestern R
Slide 27: Ongoing Expansion of Asset-Light O&M Portfolio Drives Bottom-Line Growth
5 Expanding geographically Ongoing Expansion of Asset-Light O&M Portfolio Drives Bottom-Line Growth O&M opportunities in the UAE and MENA 2024 O&M projects FY’24 Al • Stakeholder: ADNOC Group (Corporate) 188,000+ Approach Dhannah • Specifications: Multi-specialty hospital in Al Dhafrah, Abu Dhabi Pa
Slide 28: Leveraging Digital Transformation to Enhance Patient Experience
6 Accelerating digitization Leveraging Digital Transformation to Enhance Patient Experience and Maximise Operational Efficiency Strategic digital initiatives Key digital achievements Patient digital channel • Mid-term key investment areas in Digital Health Mobile application • Oracle Health informat
Slide 29: Cash-Generative Business Model Enabling Consistent Shareholder Return
7 Cash-generative business model Cash-Generative Business Model Enabling Consistent Shareholder Return Financial performance underpinned Robust margin expansion drivers by operational excellence Healthy payer-mix with proportion Significant capacity to ramp-up of Thiqa patients increasing high growt
Slide 30: Management
8 Commitment to ESG Strong Leadership with Well-Established Public Market-Oriented Corporate Governance Highly experienced leadership with focus on growing shareholder value Strong governance framework BoD of 7 Members Committees: A B N B A N 70% Independent Directors B Business Development & Sustai
Slide 31: Strategic Pillars – ESG Framework
8 Commitment to ESG Strategic Pillars – ESG Framework System Community Governance Environment Diversity Equity & Inclusion Community Engagement Corporate Governance GHG Emissions & Carbon Neutrality 1 Increase the representation of women in 1 To touch >7 million lives per year by 2026 1 Maintain a h
Slide 32: FY 2024 ESG Highlights
8 Commitment to ESG FY 2024 ESG Highlights System Community Governance Environment 95% 87% 70% -29% Employee Inpatient Independent GHG satisfaction score satisfaction score Directors emission 54% 100% Zero -35% Women in Healthcare staff completed Data breaches, corruption or GHG intensity employees
Slide 33: Sustainability Management System
8 Commitment to ESG Sustainability Management System ESG Governance on Board Level ESG Governance on Executive Level Board level Board of Directors Executive ESG Committee Chief Executive Officer Committee level NRC Committee Audit Committee Chief Finance Chief Operating Chief Medical Head of Intern
Slide 34: Performance Update
04 Performance Update Leading Super-Specialty Healthcare Provider in MENA
Slide 35: Strategic Investments Driving Future Growth
5 Expanding geographically Strategic Investments Driving Future Growth Key 2024 Strategic Spendings 2024 Mid-Term Financial Growth Financial Total Revenue Bed Capacity Utilization Ramp-up of Assets Impact • Expanded oncology patient base by growing the medical oncology segment by 40% (low-yield & ma
Slide 36: Delivering Robust Patient Footfall Growth On the Back of Continued Market Penetration
Delivering Robust Patient Footfall Growth On the Back of Continued Market Penetration Group inpatient footfall, k Group outpatient footfall, k % bed occupancy % OP utilisation 64% 70% 61% 67% 73% 69% 72% 69% • Strong inpatient footfall growth in Q4’24 & FY’24, • Outpatient footfall growth in Q4’24 &
Slide 37: Investment in Network Expansion & Complex Care To Drive Future Revenue Growth
Investment in Network Expansion & Complex Care To Drive Future Revenue Growth & Higher Yields Group Revenue, AED m Group EBITDA, AED m • Top-line growth remained steady in Q4’24, • Q4’24 EBITDA ex-one-offs declined by 28.4% YoY, 1,305 +AED 87m increasing by 7.2% YoY, supported by robust patient foot
Slide 38: Burjeel Medical City Strategically Positioned to Drive High-Yield Patient Growth
5 Expanding geographically Burjeel Medical City Strategically Positioned to Drive High-Yield Patient Growth & Margin Expansion Total patients, k Revenue, AED m1 EBITDA, AED m1 % bed occupancy 54% 68% 48% 62% +18.4% 1,205 +26.3% +21.9% 1,018 539 192 427 157 +16.0% +22.0% +1.3% 326 151 281 49 50 124 Q
Slide 39: Strategic Investments in Business Expansion to Unlock Significant Growth Potential
Strategic Investments in Business Expansion to Unlock Significant Growth Potential Group OPEX breakdown,1 as % of revenue Group EBITDA analysis, AED m 84.4% 81.2% 76.7% 78.1% +475 (173) 12.8% 10.2% (239) 9.4% 9.1% 2.2% 2.1% 2.3% 1.9% (19) Other2 1,033 1,018 (96) (41) 25.2% 25.3% (8) 959 23.8% 24.2%
Slide 40: Free Cash Flow & Operating Cash Flow Performance
Free Cash Flow & Operating Cash Flow Performance Free cash flow,1 AED m Cash flow from operating activities, AED m % FCF conversion2 64% 42% 51% 51% 566 523 500 497 489 358 366 328 163 2021 2022 2023 2024 2020 2021 2022 2023 2024 AED m 2021 2022 2023 2024 Commentary EBITDA ex-one-offs3 779 878 1,018
Slide 41: Maintaining a Robust Balance Sheet
Maintaining a Robust Balance Sheet AED m FY 2022 FY 2023 FY 2024 Debt maturity as of 31 December 2024 Bank balances and cash 150 170 238 Interest-bearing loans and borrowings 1,261 1,164 1,208 220 215 187 190 Bank overdrafts – – -- 180 Bank debt1 1,261 1,164 1,208 133 Net debt 1,111 994 970 85 2 Lea
Slide 42: Strong Profitability Outlook With Continued Commitment to Dividends
Strong Profitability Outlook With Continued Commitment to Dividends Group net profit analysis, AED m Dividends & Buyback % net profit margin • BoD-Proposed Share Buyback: +475 (526) up to 10% of share capital through open market purchases, fully funded by operating cash flow, subject to shareholder
Slide 43: Guidance
05 Guidance Leading Super-Specialty Healthcare Provider in MENA
Slide 44: Revenue & EBITDA Growth Catalysts for 2025
5 Expanding geographically Revenue & EBITDA Growth Catalysts for 2025 2025 Revenue Growth Drivers (% Contribution): Total Revenue 10% 30% 30% New Expansion Projects 15% 25% BMC & Complex Care Expansion 20% Ramp-up of Centers Opened in 2024 AED 5.0bn Mid-Teens 15% Operations & Maintenance (O&M) Proje
Slide 45: Positive Outlook Reiterated
Positive Outlook Reiterated FY 2025 (Expected) Mid-term (2026-2028) • UAE: 1 advanced care oncology center (Dubai), 1 • UAE: 1 hospital (Dubai), 1 day surgery center (Ras Al-Khaimah), 3 Expansion fertility clinic (Al Ain), 6 medical center medical center • KSA: 31 PhysioTherabia centers,1 day surger
Slide 46: Appendix
06 Appendix Leading Super-Specialty Healthcare Provider in MENA
Slide 47: Track-record of Consistent Growth
Track-record of Consistent Growth 2007-2010 2015 2017 2019 2021 2023 First Hospital opened Medeor Brand New unique facility focused on minimal Launched New Clinical Research Launched The Paley Middle East Clinic, in 2007 under LLH Launch invasive surgeries and alternative Burjeel Hospital capabiliti
Slide 48: GCC Healthcare Market Growth Drivers
GCC Healthcare Market Growth Drivers Under-penetration of healthcare expenditure 1 Strong economic growth 2 3 Favorable demographic trends vs developed countries CAGR ‘22-31E of GDP1 Healthcare expenditure as % of GDP1 +1.9% +31.9% +4% +3% +3% 4-5% 12% 19% CAGR ‘22-27E CAGR ‘22-27E of GCC UAE Oman K
Slide 49: Main Trends in Organ Transplant and Oncology Specialties in the UAE
Main Trends in Organ Transplant and Oncology Specialties in the UAE Organ transplant Oncology Total number of organ transplants performed in the UAE Total number of malignant cancer cases in UAE (k) CAGR 17-22 CAGR 2011-2022 5.0 Living 213 4.6 4.7 4.8 4.9 Deceased 184 16% 7.3% 4.0 4.1 71 3.6 3.6 3.7
Slide 50: Healthcare is a Key Focus for GCC Governments
Healthcare is a Key Focus for GCC Governments UAE initiatives Oman Health Vision 2050 KSA Vision 2030 UAE Vision 2021 To achieve sustainable funding for Some of the key initiatives health research by ensuring national in the healthcare spectrum: Providing world-class healthcare and international col
Slide 51: Group & Segment Summary
Group & Segment Summary Group financial summary Segmental financial summary2 AED millions FY’24 FY‘23 AED millions FY’24 FY‘23 Revenue 5,010 4,535 Revenue 5,010 4,535 Inventories consumed (1,269) (1,096) Hospitals3 4,406 4,026 Doctors’ and other employees’ salaries (2,186) (1,947) Medical Centers3 4
Slide 52: Investor Relations
Investor Relations March 2025 Sergei Levitskii Director of Investor Relations sergei.levitskii@burjeelholdings.com T: +971 2 3041 111 ir@burjeelholdings.com F: +971 2 2222 363 M: +971 503802383 PO Box 7400, Abu Dhabi, UAE Investor Calendar Company Website
Burjeel Holdings — Investor Presentation (March 2025) on 6ix